Faculty of Commerce, Law and Management, University of the Witwatersrand, Johannesburg 2050, South Africa.
Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban 4041, South Africa.
Viruses. 2020 Jul 10;12(7):746. doi: 10.3390/v12070746.
Currently, the treatment of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) [HBV-HCC] relies on blunt tools that are unable to offer effective therapy for later stage pathogenesis. The potential of miRNA to treat HBV-HCC offer a more targeted approach to managing this lethal carcinoma; however, the complexity of miRNA as an ancillary regulator of the immune system remains poorly understood. This review examines the overlapping roles of HBx-dysregulated miRNA in HBV-HCC and immune pathways and seeks to demonstrate that specific miRNA response in immune cells is not independent of their expression in hepatocytes. This interplay between the two pathways may provide us with the possibility of using candidate miRNA to manipulate this interaction as a potential therapeutic option.
目前，乙型肝炎病毒（HBV）相关肝细胞癌（HCC）[HBV-HCC]的治疗依赖于无法为后期发病机制提供有效治疗的钝器。miRNA 治疗 HBV-HCC 的潜力为管理这种致命的癌提供了更具针对性的方法；然而，miRNA 作为免疫系统辅助调节剂的复杂性仍知之甚少。本综述探讨了 HBx 失调 miRNA 在 HBV-HCC 和免疫途径中的重叠作用，并试图证明免疫细胞中特定 miRNA 的反应与其在肝细胞中的表达并不独立。这两条途径之间的相互作用可能为我们提供了使用候选 miRNA 来操纵这种相互作用的可能性，作为一种潜在的治疗选择。
